RxDoctor Payments Data

Madisen McKell, PA

Physician Assistant · Lehi, UTNPI 1508592767

Payments from drug & device makers

$1,998in general payments, 2019–2025

Across 110 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$554
  • Johnson & Johnson$333
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • Lilly USA, LLC$137
  • Idorsia Pharmaceuticals US Inc$110
  • Novo Nordisk$96
  • plus $608 from 18 others

What the payments were for

  • Food & beverage$1,998100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,998 in reported general payments places this provider in the 80th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$22,183
Medicare patients
82
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban16$17,363
MounjaroTirzepatide15$15,803
OzempicSemaglutide15$15,373
Gabapentin50$1,092
Atorvastatin Calcium62$1,008
Bupropion XlBupropion Hcl43$992
Omeprazole45$977
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$953
Celecoxib26$905
Levothyroxine Sodium70$858
Duloxetine Hcl23$606
Zolpidem Tartrate53$560
Sertraline Hcl38$547
Clonazepam16$493
Losartan Potassium48$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$17,36316 claims
Lilly USA, LLCMounjaro$137$15,80315 claims
Novo NordiskOzempic$96$15,37315 claims
Almatica Pharma LLCSertraline Hcl$13$54738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Lehi

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →